Advertisement

Patch Problems? Characteristics of Transdermal Drug Delivery System Exposures Reported to the National Poison Data System

  • Stephen L. ThorntonEmail author
  • Micheal A. Darracq
Original Article

Abstract

Background

Transdermal drug delivery systems (TDDS) pose special risks considering a large amount of drug they contain and their modified release properties. We sought to characterize TDDS exposures reported to the National Poison Data System (NPDS).

Methods

NPDS was searched for all human exposures to a TDDS from 1/1/2006 to 12/31/2015. Only single-substance TDDS exposures followed to a known medical outcome were included for final analysis. Specific data analyzed was date, sex, age, TDDS product, exposure reason, route of exposure, medical outcome, management site, level of health care facility care, clinical effects, and interventions.

Results

Over that 10-year period, 6746  adults and 1917 pediatric exposures were identified. Exposures declined over the study period. The most common exposure reason in adults was intentional abuse (n = 1622) compared to unintentional-general (n =1 070) in pediatric cases. TDDS ingestion was reported in 4519 adults and 2825 pediatric cases. Fentanyl was the most common substance encountered in adult (n = 4656) and pediatric cases (n = 474). No or minor effect were the most common medical outcomes in both groups. In fentanyl cases, moderate or major outcomes were seen in 54 % (n = 1062) of adult and 26 % (n = 54) of pediatric cases. Naloxone was given in 1080 cases. Ninety-seven deaths (91 adults, 6 pediatrics) were reported, all involving ingestion of the TDDS. Fentanyl was associated with 80 adult and 5 pediatric deaths.

Conclusion

Overall, single-substance TDDS exposures decreased over the duration of this study and typically resulted in no or mild effects. However, exposures involving fentanyl resulted in higher rates of major or moderate medical outcomes and were associated with multiple deaths.

Keywords

Transdermal drug delivery system Patch Fentanyl Methylphenidate Naloxone 

Notes

Compliance with Ethical Standards

Conflicts of Interest

None.

Sources of Funding

None.

References

  1. 1.
    Magner LN. A history of medicine. Boca Raton: Taylor & Francis; 2005.CrossRefGoogle Scholar
  2. 2.
    Transdermal scopolamine for motion sickness. Med Lett Drugs Ther. 1981;23(21):89–90.Google Scholar
  3. 3.
    Weber MA, Drayer JI, McMahon FG, Hamburger R, Shah AR, Kirk LN. Transdermal administration of clonidine for treatment of high BP. Arch Intern Med. 1984;144(6):1211–3.CrossRefGoogle Scholar
  4. 4.
    National Drug Code Directory. Fda.Gov, 2019, https://www.fda.gov/Drugs/InformationOnDrugs/ucm142438.htm. Accessed Feb 5 2019.
  5. 5.
    Schmid-Grendelmeier P, Pokorny R, Gasser UE, Richarz U. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers. Curr Med Res Opin. 2006;22(3):501–9.CrossRefGoogle Scholar
  6. 6.
    Duragesic (fentanyl transdermal system) package insert, Janssen Pharmaceutical Products, L.P, Titusville, NJ USA 08560;Google Scholar
  7. 7.
    Catapress-TTS (clonidine) package insert, Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT USA 06877.Google Scholar
  8. 8.
    Woodall KL, Martin TL, McLellan BA. Oral abuse of fentanyl patches (Duragesic®): seven case reports. J Forensic Sci. 2008;53(1):222–5.CrossRefGoogle Scholar
  9. 9.
    Rapko DA, Rastegar DA. Intentional clonidine patch ingestion by 3 adults in a detoxification unit. Arch Intern Med. 2003;163(3):367–8.CrossRefGoogle Scholar
  10. 10.
    Carson HJ, Knight LD, Dudley MH, Garg U. A fatality involving an unusual route of fentanyl delivery: chewing and aspirating the transdermal patch. Leg Med (Tokyo). 2010;12(3):157–9.CrossRefGoogle Scholar
  11. 11.
    Marquardt KA, Tharratt RS. Inhalation abuse of fentanyl patch. J Toxicol Clin Toxicol. 1994;32(1):75–8.CrossRefGoogle Scholar
  12. 12.
    Marquardt KA, Tharratt RS, Musallam NA. Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother. 1995;29(10):969–71.CrossRefGoogle Scholar
  13. 13.
    Flannagan LM, Butts JD, Anderson WH. Fentanyl patches left on dead bodies --potential source of drug for abusers. J Forensic Sci. 1996;41(2):320–1.CrossRefGoogle Scholar
  14. 14.
    Nelson L, Schwaner R. Transdermal fentanyl: pharmacology and toxicology. J Med Toxicol. 2009;5(4):230–41.CrossRefGoogle Scholar
  15. 15.
    Zhang XC, Farrell N, Haronian T, Hack J. Postoperative anticholinergic poisoning: concealed complications of a commonly used medication. J Emerg Med. 2017;53(4):520–3.CrossRefGoogle Scholar
  16. 16.
    Shemirani N, Tang D, Friedland DR. Acute auditory and vestibular symptoms associated with heat and transdermal lidocaine. Clin J Pain. 2010;26(1):58–9.CrossRefGoogle Scholar
  17. 17.
    National Poison Data System. https://aapcc.org/data-system. Accessed May 24, 2019.
  18. 18.
    Watkinson AC, Kearney MC, Quinn HL, Courtenay AJ, Donnelly RF. Future of the transdermal drug delivery market--have we barely touched the surface? Expert Opin Drug Deliv. 2016;13(4):523–32.CrossRefGoogle Scholar
  19. 19.
    Bakovic M, Nestic M, Mayer D. Death by band-aid: fatal misuse of transdermal fentanyl patch. Int J Legal Med. 2015;129(6):1247–52.CrossRefGoogle Scholar
  20. 20.
    Position paper: whole bowel irrigation. J Toxicol Clin Toxicol. 2004;42(6):843–54. Review. Erratum in: J Toxicol Clin Toxicol. 2004;42(7):1000.Google Scholar
  21. 21.
    Arroyo Plasencia AM, Mowry J, Smith J, Quigley K. In vitro release of fentanyl from transdermal patches in gastric and intestinal fluid. Clin Toxicol (Phila). 2014;52(9):945–7.CrossRefGoogle Scholar
  22. 22.
    Horowitz R, Mazor SS, Aks SE, Leikin JB. Accidental clonidine patch ingestion in a child. Am J Ther. 2005;12(3):272–4.Google Scholar
  23. 23.
    Moffatt K, Wang Y, Raj Singh TR, Donnelly RF. Microneedles for enhanced transdermal and intraocular drug delivery. Curr Opin Pharmacol. 2017;36:14–21.CrossRefGoogle Scholar

Copyright information

© American College of Medical Toxicology 2019

Authors and Affiliations

  1. 1.University of Kansas Health System Poison Control CenterUniversity of Kansas HospitalKansas CityUSA
  2. 2.Department of Emergency MedicineUniversity of California- San Francisco-FresnoFresnoUSA

Personalised recommendations